Overview of Mental Health Medications for Children and Adolescents

Module 2 Depressive Disorders

### Depression in Adolescents

- \* Major Depressive Disorder
  - \* Persistent depressed mood and/or irritability

1

2

3

- \* Vegetative symptoms
- \* Lasting at least 2 weeks
- \* Dysthymia
  - \* Persistent depressed mood and/or irritability
  - \* Low self esteem
  - \* Tiredness
  - Decreased concentration
  - \* At least 1 yr in duration

# Symptoms in Youth

- \* Sadness that doesn't go away
- \* Altered sleep, appetite or energy
- \* Loss of interest in usual activities
- \* Missed school or poor academic performance
- \* Physical symptoms
- \* Irritable, fighting, difficulty concentrating
- $\boldsymbol{\star}$  Feeling hopeless, withdrawn
- \* Thoughts of suicide, death, running away

## Symptoms in Pre-pubertal Youth


- \*Separation anxiety
- \*Somatic complaints
- \*Behavioral complaints (aggression)
- \*Poor school performance
- \*Changes in sleep and energy

#### Suicide Risk

- \* Major depressive disorder
- \* Family history of mood disorder or suicide
- \* Previous suicidal behavior
- \* Substance abuse
- Psychosocial stressors (ie loss of family member)
- \* Family violence
- \* Rejection or humiliation

## Suicide Warning Signs

- \* Becoming cheerful after period of depression
- \* Putting affairs in order
- \* Future planning stops
- \* Comments
  - \* "I won't be a problem much longer"
  - \* "You don't need to worry about me"





## Antidepressants: Onset of Action

- \* Clinical effect is usually not manifest for 1-3 weeks
- Clinical rule is usually to treat patient for a minimum of 6 wks at an adequate dosage before changing
- \* Synaptic effects occur immediately (hrs)
- \* Adverse effects have same time course as synaptic effects

NE transporter blockade	Tremors, Tachycardia, Enhanced effects of sympathomimetics Reflex tachycardia, Orthostatic hypotension		
Alpha <sub>1</sub> blockade			
Antihistamine effects	Sedation, Weight gain, Potentiation of central depressant drugs		
Anticholinergic effects	Blurred vision, Dry mouth, Tachycardia, Constipation, Urinary retention		



	Adverse E	oort Blockers: Effects
Receptor	Location	Side Effect
2A/2C	Raphe to limbic	Agitation, anxiety, panic attacks
2C	Basal ganglia	Akathisia, dystonia, parkinson-like actions
2A	Brainstem	Myoclonus
2A	Mesocortical	Apathy
3/4	GI tract	Increased GI activity, diarrhea

### Antidepressants

- \* Selective serotonin reuptake inhibitors preferred
- \* Fluoxetine (Prozac) FDA approved 8-18 yrs
- \* Escitalopram (Lexapro) FDA approved 12-17 yrs
- \* Fluvoxamine
- \* Sertraline (Zoloft)
- \* Citalopram (Celexa)
- \* Paroxetine (Seroxat, Paxil CR)

## SSRIs - Adverse Effects

- \* Suicide
- **\*** GI symptoms
- \* Change in appetite
- \* Sedation/activation
- \* Increased sweating
- \* Rare: Serotonin syndrome

12

## Antidepressants

- \* Selective Norepinephrine Reuptake inhibitors (SNRIs) – increase NE and 5-HT
- \*Include
  - \*Duloxetine (Cymbalta)
  - \*Venlafaxine (Effexor, Effexor XR)
  - \*Desvenlafaxine (Pristiq)

## SNRI- Adverse Effects

13

14

15

\*Suicide

**\***GI symptoms

\*Change in appetite

\*Sedation or activation

\*Increased sweating

### Antidepressants

\* Tricyclic antidepressants – inhibit NE re-uptake

\* Considered less safe due to side effects

\* Include:

- \* Amitriptyline FDA (9-12 yrs)
- \* Amoxapine
- \* Clomipramine (Anafranil)
- \* Desipramine (Norpramin)
- \* Doxepin (Silenor)
- \* Imipramine (Tofranil)- FDA (6-12 yrs; >12 yrs)
- \* Nortriptyline (Pamelor)- FDA (6-12 yrs; > 12 yrs)
- Trimipramine (Surmontil) FDA (>12 yrs)

## TCAs – Adverse Effects

- \* GI symptoms
- \* Change in appetite
- \* Anticholinergic symptoms dry mouth

16

17

\* Tachycardia

### Misc Antidepressants

- \* Inhibit reuptake of NE and DA and other mechanisms
- \* Include
  - \* Bupropion
  - \* Maprotiline
  - \* Mirtazapine (Remeron)
  - \* Nefazodone
  - \* Trazodone

#### Suicide Risk - Antidepressants

#### Suicidality and Antidepressant Drugs (2007 BBW update)

Suicidality and Antidepressant Drugs (2007 BBW update) Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of [Insert established name] or any other antidepressant in a child, adolescent, or young adults in sylend age 24; there was a reduction in risk with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicidal. Patients of all ages who are started on antidegressant the risk of suicida. Patients of all ages observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. [Insert Drug Name] is not approved for use in pediatric patients. [The previous sentence would be replaced with the sentence, below, for the following drugs: Proza: <u>Proza is approved for use in pediatric patients</u> with MDD and obsessive compulsive disorder (QCD). Zoloft: Zoloft is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (DCD). Plovoxamine: Elivoxamine is not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD). 18